News

Xeris’ G-Pen Mini (glucagon injection), a room-temperature stable glucagon product, is intended to be an effective and convenient treatment for mild-to-moderate hypoglycemia or low blood sugar. Currently, glucagon

The results will also appear in a forthcoming print issue of the journal. The authors note that ESTABLISH-2 was the first prospectively designed clinical trial consistent with the

The biopharmaceutical firm is focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones. The company said that

Eloctate [antihemophilic factor (recombinant), Fc fusion protein] is the first haemophilia A therapy with prolonged circulation in the body. It reduces the frequency of bleeding episodes with prophylactic

The API will be manufactured in ScinoPharm’s plant in Changshu, China. This cooperation not only demonstrates Taiwan’s international competitive strength in new drug development, but also sees the

BUNAVAIL is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. BDSI

The 220,000-square-foot expansion was announced by Huntsman at the annual fundraising gala last November. With Architectural Nexus as the architect and Jacobsen Construction as the builder, the addition

Earlier in 2014, the US Food and Drug Administration (FDA) had approved Pradaxa to treat patients with DVT and PE. The company said that almost one in three

The expansion is anticipated to be fully operational end of the first quarter of 2015. The new 2,000 L single-use bioreactor will supplement two existing 1,000 L single-use